Dr. Ningyan Zhang is a professor at the John P. and Kathrine G. McGovern Medical School, the University of Texas Health Science Center (UTHealth) in Houston. She received her Ph.D. in plant biochemistry/molecular biology from the University of Kentucky in 1992. She had her postdoctoral training in protein biochemistry at the University of Wisconsin-Madison. Following her postdoctoral training, she started her career in the pharmaceutical industry and worked on protein engineering and therapeutic antibody drug discovery research. Dr. Zhang was recruited as a Texas ETF (Emerging Technology Fund) Scholar and joined the Institute of Molecular Medicine (IMM) at UTHealth Houston in 2010. Since joining UTHealth, she has continued pursuing her interest in translational research with a focus on the evaluation of new cancer targets and the development of platform technologies for therapeutic antibody discovery in the academic setting. She is also the Co-Director of the CPRIT Therapeutic Antibody Core. She manages collaborative projects and communicates with outside collaborators from many research institutions, including the University of Texas MD Anderson Cancer Center, Balor College of Medicine, and University of Texas Southwestern Medical Center. The Antibody Core currently has more than 10 active collaborative projects with a focus on the discovery of therapeutic antibodies targeting various cancer types.